Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA
Portfolio Pulse from
Achieve Life Sciences has announced plans to advance its vaping cessation therapy, Cytisinicline, following a successful end-of-Phase 2 meeting with the FDA. This milestone highlights the potential of Cytisinicline as a first-in-class treatment for vaping cessation.

December 03, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Achieve Life Sciences is progressing with Cytisinicline, a potential first-in-class therapy for vaping cessation, after a successful FDA meeting.
The successful end-of-Phase 2 meeting with the FDA is a significant milestone for Achieve Life Sciences, indicating regulatory progress and potential market entry for Cytisinicline. This development is likely to positively impact ACHV's stock price in the short term as it reinforces the drug's potential as a first-in-class treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100